ZIOPHARM Oncology Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZIOPHARM Oncology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZIOP, but not buy additional shares or sell existing shares.
View analyst ratings for ZIOPHARM Oncology or view top-rated stocks.

Wall Street analysts have given ZIOPHARM Oncology a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ZIOPHARM Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ZIOPHARM Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for ZIOPHARM Oncology.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) issued its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($0.10) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.01. During the same quarter last year, the company posted ($0.09) earnings per share.
View ZIOPHARM Oncology's earnings history.

ZIOPHARM Oncology's stock was trading at $2.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ZIOP shares have increased by 24.8% and is now trading at $3.17.
View which stocks have been most impacted by COVID-19.

5 brokerages have issued twelve-month price objectives for ZIOPHARM Oncology's shares. Their forecasts range from $4.00 to $7.50. On average, they anticipate ZIOPHARM Oncology's share price to reach $5.63 in the next twelve months. This suggests a possible upside of 77.4% from the stock's current price.
View analysts' price targets for ZIOPHARM Oncology or view top-rated stocks among Wall Street analysts.

Some companies that are related to ZIOPHARM Oncology include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of ZIOP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN), Gilead Sciences (gild), OPKO Health (OPK), (CELG), Sangamo Therapeutics (SGMO), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Inovio Pharmaceuticals (INO), Arena Pharmaceuticals (ARNA) and Immunomedics (IMMU).

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

ZIOPHARM Oncology's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.68%), JPMorgan Chase & Co. (2.44%), Geode Capital Management LLC (1.64%), Northern Trust Corp (1.10%), Bank of New York Mellon Corp (0.46%) and Citigroup Inc. (0.39%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney, Groot Eleanor De, Jill Buck, Kevin G Lafond, Laurence James Neil Cooper and Robert Hadfield.
View institutional ownership trends for ZIOPHARM Oncology.

ZIOP stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Credit Suisse AG, Northern Trust Corp, Sargent Investment Group LLC, Bank of Montreal Can, Rhumbline Advisers, Commonwealth Equity Services LLC, and Chevy Chase Trust Holdings Inc.. Company insiders that have sold ZIOPHARM Oncology company stock in the last year include Groot Eleanor De, Jill Buck, Kevin G Lafond, Laurence James Neil Cooper, and Robert Hadfield.
View insider buying and selling activity for ZIOPHARM Oncology or view top insider-selling stocks.

ZIOP stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Citigroup Inc., Rafferty Asset Management LLC, Geode Capital Management LLC, Renaissance Technologies LLC, UBS Group AG, Migdal Insurance & Financial Holdings Ltd., and Dimensional Fund Advisors LP.
View insider buying and selling activity for ZIOPHARM Oncology or or view top insider-buying stocks.

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ZIOP stock can currently be purchased for approximately $3.17.

ZIOPHARM Oncology has a market capitalization of $683.21 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-117,800,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

ZIOPHARM Oncology employs 103 workers across the globe.

The official website for ZIOPHARM Oncology is www.ziopharm.com.

ZIOPHARM Oncology is headquartered at ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129.

ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]